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OBJECTIVES: To examine quality of life, work productivity, and health care resource 
use among employed adults ages 40 to 64 years with COPD. METHODS: Data were 
obtained from the US 2009 National Health and Wellness Survey (NHWS), an internet-
based questionnaire. All employed adults (full-time, part-time, or self-employed) ages 
40–64 years with or without a self-reported diagnosis of COPD were included. Impact 
on quality of life (using the mental (MCS) and physical component summary (PCS) 
scores and health utilities from SF-12v2), work productivity and activity impairment 
(using WPAI questionnaire), and resource use were analyzed. Multiple regression 
analyses for normally-distributed outcomes and negative binomial regressions for 
skewed outcomes were conducted. All models adjusted for demographic and patient 
characteristics and were weighted to project to the US population. RESULTS: There 
were 1,112 workers with COPD (mean age = 51.5 years) versus 18,912 workers 
without COPD (mean age = 50.0 years). After adjusting for demographic and patient 
characteristics, adults with COPD reported signiﬁ cantly lower mean levels of MCS 
(46.8 vs. 48.5, P < 0.0001), PCS (45.6 vs. 49.2, P < 0.0001), and health utilities (0.71 
vs. 0.75, P < 0.0001), than adults without COPD. Workers with COPD reported 
signiﬁ cantly greater impairment while at work (presenteeism) (18.9% vs. 14.3%, P < 
0.0001), overall work impairment (a combination of absenteeism and presenteeism) 
(20.5% vs. 16.3%, P < 0.0001), and impairment in daily activities (23.5% vs. 17.9%, 
P < 0.0001) than adults without COPD. Employed adults with COPD also reported 
more mean ER visits (0.21 vs. 0.12, P < 0.0001) and more mean hospitalizations (0.10 
vs. 0.06, P < 0.0001) in the previous six months than employed adults without COPD. 
CONCLUSIONS: After adjusting for various demographic and patient characteristics, 
employed adults with COPD reported signiﬁ cantly worse quality of life, work pro-
ductivity, and health care resource utilization than employed adults without COPD. 
These results highlight the substantial impact and burden of COPD in the US 
workforce.
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OBJECTIVES: Several pharmacological therapies are available to help smokers quit. 
We determined utilization and effectiveness of smoking cessation therapy (SCT) in 
daily practice in the The Netherlands. METHODS: Subjects ≥18 years with a dispens-
ing of varenicline, bupropion, nicotine or nortriptyline between March 2007 and 
September 2008 were identiﬁ ed from the PHARMO RLS. Using an encrypted meth-
odology, the corresponding non-person-identiﬁ able dispensing IDs were linked to a 
web-based system for patient-reported data collection: ePRO-LINK. Corresponding 
pharmacists asked the subjects to participate in the study and complete a web-based 
questionnaire on smoking history and cessation. RESULTS: Of 2,684 invited subjects, 
612 were included in the analyses. Bupropion was the most frequently used SCT 
during last quit attempt (35%), followed by varenicline (28%), bupropion + nicotine 
(12%) and varenicline + nicotine (9%). Overall, 51% of patients also reported behav-
ioural therapy. About 52% of varenicline and bupropion users, 42% of nicotine users 
and 20–40% of patients using multiple drugs reported not to smoke at the time of 
questionnaire. The median (IQR) number of days between time of questionnaire and 
start date of last quit attempt ranged from 271 (104–432) for varenicline + bupropion 
to 356 (205–518) for bupropion. The mean duration of drug use ranged from 42–53 
days among SCT users who remained abstinent and from 19–42 days among SCT 
users who relapsed. CONCLUSIONS: The results of this study show that up to 50% 
of SCT users in daily practice quit smoking. More widespread use of these drugs in 
combination with behavioural therapy will help to further decrease smoking 
prevalence.
PRS41
FACTORS AFFECTING QUALITY OF LIFE (QOL) OF ASTHMATIC 
PATIENTS IN SPAIN
Martinez-Moragon E1, Palop M2, de Diego A3, Serra J4, Caloto T5, Nocea G5, Sabater E6
1Hospital de Sagunto, Valencia, Spain; 2Hospital Universitario La F, Valencia, Spain; 3Hospital 
Universitario La Fe, Valencia, Spain; 4Hospital General de Vic, Barcelona, Spain; 5Merck Sharp 
& Dohme, SA, Madrid, Spain; 6Pharmacoeconomics & Outcomes Research Iberia, Pozuelo, 
Spain
OBJECTIVES: Understanding and identifying impaired QoL is now recognised as an 
important component of asthma management.To assess QoL and factors inﬂ uencing 
it, in asthmatic patients in Spain. METHODS: Observational, multicenter study was 
carried out in 40 Spanish pneumology units. Asthma diagnosed patients (according 
to GINA) aged ≥18 were enrolled. Disease severity and treatment information were 
investigator-reported, and socio-demographic data, symptoms, and QoL (self admin-
istered Mini Asthma Quality of Life Questionnaire ,Mini AQLQ) were patient-
reported. Optimal scaling methods for multivariate categorical data were conducted. 
RESULTS: A total of 536 patients were studied (mean age 54 years; 65% female). 
Signiﬁ cant differences in Mini-AQLQ total scores were observed by disease severity 
according to GINA: 4.3 (SD 1.3) for severe persistent, 4.9 (SD1.2) for moderate 
persistent, 5.4 (SD 1.0) for mild persistent and 5.7 (SD1.0) for intermittent patients 
(P < 0.0001). As per the ﬁ nal multivariate model (with MiniAQLQ total score as 
dependent variable and after adjusting for all signiﬁ cant variables in the bivariate 
analysis), reported QoL was better for patients from Northern and Central Spain as 
compared with those from the South and the East (P < 0.0001), students and employed 
patients as compared with housewives and unemployed (p = 0.001), for those who 
had received information about the disease compared with those who did not (p = 
0.004), for those with milder daytime symptoms (p = 0.001) and for patients with 
higher education (p = 0.021). CONCLUSIONS: Modiﬁ able factors such as symptom 
control and adequate information about asthma can have a signiﬁ cant effect on 
patients’ QoL. 
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OBJECTIVES: Asthma symptoms are adequately controlled in fewer than 25% of 
asthmatic children. The objective was to identify the determinants of severe exacerba-
tion resulting in Emergency Department visits or hospitalization related to health 
status, socioeconomic status (SES) and drug insurance characteristics. METHODS: In 
this retrospective cohort study, data were collected on 522 asthmatic children in 
Toronto, Canada, regarding demographics, SES, drug plan characteristics, health 
status, health resource use and symptoms. Baseline data were linked deterministically 
to administrative data on asthma emergency visits and hospitalizations occurring in 
the year following baseline. Multiple Poisson regression was conducted to identify 
independent predictors of severe exacerbation in the full cohort and in a sub-group 
with prescription drug insurance. RESULTS: Younger age, prior emergency visits, 
nebulizer use, pet ownership, and receipt of asthma education, but no asthma action 
plan, were signiﬁ cant determinants of more frequent exacerbation. In the full cohort, 
children with high income adequacy had 28% fewer exacerbations than children with 
low income adequacy. In the sub-group with drug insurance, girls had 26% fewer 
exacerbations than boys, and children with food, drug or insect allergies had 52% 
more exacerbations than children without such allergies. Children of families with 
annual insurance deductibles greater than $90 had 95% fewer exacerbations. In addi-
tion, every percentage increase in the proportion of income spent out-of-pocket on 
asthma medications resulted in a 14% increase in severe exacerbations. CONCLU-
SIONS: Asthma history, disease management factors and SES were important deter-
minants of severe asthma exacerbation in children. In families with drug plans, the 
magnitude of asthma medication cost-sharing as a proportion of household income, 
rather than income alone, was a highly signiﬁ cant determinant of severe exacerbation. 
This ﬁ nding can inform drug policies aimed at reducing the negative consequences of 
cost-sharing.
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OBJECTIVES: Recent Italian studies showed that ICS-containing (Inhaled corticoste-
roids) drugs are prescribed to more than 50% of COPD patients regardless of disease 
severity and treatment guidelines, creating unnecessary costs for NHS. This study aims 
at assessing potential saving on drugs expenditure due to increased compliance to 
GOLD guidelines. METHODS: Novartis Core-model framework was adapted to 
Italian setting. Patient cohort was deﬁ ned by applying prevalence rate of treated COPD 
patients to Italian population (2.5% annual growth rate). Patients severity split and 
treatment pattern are obtained by combining results of two Italian observational 
studies (reﬂ ecting GPs and pneumologists setting), assumed to be constant over 5 
years. Drugs considered: LAMA (Long-acting muscarinic antagonist), LABA (Long-
acting β2-agonist), Fixed-Dose Combination (LABA+ICS), SABA (Short-acting 
β2-agonist), add-on ICS. Based on reimbursed net public price, daily treatment costs 
for drugs are calculated. To calculate annual treatment cost, 50% compliance for all 
drugs (except 30% for ICS) and annual discounting rate of 3.0% are assumed. Fol-
lowing GOLD treatment scheme, Mild and Moderate patients, receiving long-acting 
bronchodilators and/or add-on ICS, were assigned respectively to SABA and LABA/
LAMA alone. Difference in drugs costs between current and modiﬁ ed treatment 
pattern is calculated. RESULTS: Potential saving, calculated for Italy, was c160.2 
million (36.4% of total drug costs) in year 1, and c793.4 million (36.4%) over 5 years. 
Analysis was extended to regional populations, resulting in one-year savings of: c26 
million in Lombardy, from c10 million to c15 million in Campania, Lazio, Sicily, 
Veneto, Piedmont, Emilia Romagna, Apulia, Tuscany, from c3 million to c5 million 
in Calabria, Sardinia, Liguria, Marche, Abruzzo, Friuli-Venezia Giulia, Trentino-Alto 
Adige, and up to c2 million in Umbria, Basilicata, Molise, Aosta Valley. Results were 
